A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1222 participants.
Also called NCT06522997
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,222 participants
- Sponsor
- Registry
-
NCT06522997 -
2023-505755-40-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Belgium, China, Greece, India, Italy, Japan, Portugal, Singapore, Slovakia, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06522997. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-08 (actual); primary completion 2025-10-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
- Acronym
- ALPINE 1
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- BAY3283142
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct06522997- Content hash
7d24d0304e2343decd5609ec8cc965bb6161c405b6d274f026a1897c58968d81